AKT1 and neoplasm: This degradation of GCN5 is inhibited by AKT activation, leading to increased GCN5 protein levels and subsequently higher levels of LIFR‐K620 acetylation in PTEN‐null tumour cells, eventually forming a positive feedback loop to sustain constitutive AKT pathway activation.